Clinical Trial Update: Safety and Efficacy Study of Neovasculgen (Pl-VEGF165) Gene Therapy in Patients With Peripheral Nerve Injury [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update describing a safety and efficacy study of Neovasculgen (PL-VEGF165) gene therapy in peripheral nerve injury, spanning Phase 1 and Phase …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral Nerve Injury

Drugs mentioned

• Neovasculgen (VEGF165 plasmid DNA (pl-VEGF165))

Snippet

Sponsor: Artgen Biotech | Conditions: Peripheral Nerve Injury | Phase 1, Phase 2 | Status: UNKNOWN